<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821819</url>
  </required_header>
  <id_info>
    <org_study_id>IB012016</org_study_id>
    <nct_id>NCT02821819</nct_id>
  </id_info>
  <brief_title>Random-start Ovarian Stimulation in Egg-donors (ROSE)</brief_title>
  <acronym>ROSE</acronym>
  <official_title>Random-start Ovarian Stimulation in Egg-donors (ROSE) Trial: a Self-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective single-center study is to evaluate the laboratory outcome
      after random start ovarian stimulation in oocytes donors. The study will be performed in
      egg-donors but this type of treatment has the potential to be implemented in general
      infertility population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study group will start ovarian stimulation randomly in different moments throughout the
      menstrual cycle.

      Randomization will take place on day 2-3 of the menstrual cycle, according to a list of
      random allocation of treatments and egg-donors will be assigned to random start ovarian
      stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle
      and during luteal phase starting at LH peak +3,+5,+7,+9 or +11.

      Egg-donors will receive urinary FSH 150-225 IU/d in antagonist protocol cetrorelix acetate
      0,25 mg/d starting five days after ovarian stimulation + GnRH agonist triggering with
      triptorelin 0,2 mg for final follicular maturation. Foliculometry by transvaginal ultrasound
      and serum analysis (estradiol, progesterone, LH and FSH) will be included for cycle
      monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of mature eggs</measure>
    <time_frame>Up to 24 hours from the oocyte collection</time_frame>
    <description>Rate of mature eggs / total eggs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>24 hours after day of oocyte collection</time_frame>
    <description>Fertilization rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at LH peak +3,+5,+7,+9 or +11. They will receive urinary FSH 150-225 IU/d and five days later cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 UI/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Random start ovarian stimulation</intervention_name>
    <description>Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotrophins</intervention_name>
    <description>Urinary FSH 150-225 IU/d</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <description>Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <description>GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Final follicular maturation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women

          -  18-35 years old

          -  FSH levels &lt; 10 mIU/ml

          -  AFC&gt; 10

          -  Regular cycles

          -  BMI &lt; 28

          -  Signed informed consent

        Exclusion Criteria:

          -  PCOS patients

          -  Allergy to gonadotrophins

          -  Concomitant participation in other trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Castillo, Md. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Bernabeu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan C Castillo, Md. PhD.</last_name>
    <phone>+34 965 154 000</phone>
    <email>jcastillo@institutobernabeu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan C Castillo, Md. PhD.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.institutobernabeu.com</url>
    <description>Setting</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27114329</url>
    <description>Reference</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Juan Carlos Castillo</investigator_full_name>
    <investigator_title>Md. PHd.</investigator_title>
  </responsible_party>
  <keyword>ovarian stimulation</keyword>
  <keyword>random</keyword>
  <keyword>egg donation</keyword>
  <keyword>antagonist</keyword>
  <keyword>gnrh agonist trigger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

